CAPTEM
Showing 1 - 13 of 13
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors Trial in Little Rock, Buffalo, Philadelphia (Capecitabine Oral Product,
Recruiting
- Neuroendocrine Tumor Grade 2
- Liver Metastases
- Capecitabine tablets + temozolomide tablets + SIR-Spheres
-
Philadelphia, PennsylvaniaAbramson Cancer Center
Oct 1, 2021
Glioblastoma Multiforme (GBM), Glioblastoma, Glioma of Brain Trial in New York (Capecitabine, Temozolomide)
Recruiting
- Glioblastoma Multiforme (GBM)
- +8 more
-
New York, New YorkLenox Hill Brain Tumor Center
Aug 30, 2021
Metastatic Colorectal Cancer Trial in Milan (Capecitabine, Temozolomide, Irinotecan)
Completed
- Metastatic Colorectal Cancer
- Capecitabine
- +4 more
-
Milan, Mi, ItalyFondazione IRCCS Istituto Nazionale Tumori
Sep 3, 2021
Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors Trial in Little Rock, Buffalo, Philadelphia (Capecitabine Oral Product,
Recruiting
- Neuroendocrine Tumor Grade 2
- Neuroendocrine Tumors
- Capecitabine Oral Product
- +2 more
-
Little Rock, Arkansas
- +2 more
Aug 11, 2022
Neuroendocrine Tumors Trial in Warszawa (177Lu-DOTATOC)
Unknown status
- Neuroendocrine Tumors
-
Warszawa, PolandCentrum Diagnostyczno-Lecznicze Gammed
Nov 2, 2020
Neuroendocrine Tumors Trial in Worldwide (177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine
Recruiting
- Neuroendocrine Tumors
- 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT
- +4 more
-
Palo Alto, California
- +30 more
Dec 14, 2022
Metastatic Malignant Tumor in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8 Trial
Recruiting
- Metastatic Malignant Neoplasm in the Liver
- +4 more
-
Ames, Iowa
- +5 more
Dec 3, 2021
Neuroendocrine Tumors Trial in France (Oxaliplatin-based chemo, Alkylating-based chemo)
Active, not recruiting
- Neuroendocrine Tumors
- Oxaliplatin-based chemotherapy
- Alkylating-based chemotherapy
-
Amiens, France
- +18 more
Mar 15, 2022
Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma Trial (Lutetium Lu 177 Dotatate,
Not yet recruiting
- Metastatic Pancreatic Neuroendocrine Tumor
- Unresectable Pancreatic Neuroendocrine Carcinoma
- Lutetium Lu 177 Dotatate
- +4 more
- (no location specified)
Feb 10, 2022
Metastatic Colorectal Cancer Trial in Milan (Bevacizumab, Irinotecan, Leucovorin)
Recruiting
- Metastatic Colorectal Cancer
- Bevacizumab
- +4 more
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
Apr 1, 2022
Rectal Cancer Trial in Milan (External-beam radiation, Capecitabine, Temozolomide)
Recruiting
- Rectal Cancer
- External-beam radiation
- +2 more
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori
Jan 25, 2022
Neuroendocrine Tumors Trial in Beijing (Capecitabine, Dacarbazine, Capecitabine, Temozolomide)
Unknown status
- Neuroendocrine Tumors
- Capecitabine, Dacarbazine
- Capecitabine, Temozolomide
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Sep 10, 2017